AbbVie Inc. Consolidated Net Income/Loss

Consolidated Net Income/Loss of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Consolidated Net Income/Loss growth rates and interactive chart.


Highlights and Quick Summary

  • Consolidated Net Income/Loss for the quarter ending June 29, 2021 was $752 Million (a -78.7% decrease compared to previous quarter)
  • Year-over-year quarterly Consolidated Net Income/Loss decreased by -67.25%
  • Annual Consolidated Net Income/Loss for 2020 was $4.56 Billion (a -41.83% decrease from previous year)
  • Annual Consolidated Net Income/Loss for 2019 was $7.84 Billion (a 38.62% increase from previous year)
  • Annual Consolidated Net Income/Loss for 2018 was $5.66 Billion (a 7.08% increase from previous year)
  • Twelve month Consolidated Net Income/Loss ending June 29, 2021 was $6.6 Billion (a 29.63% increase compared to previous quarter)
  • Twelve month trailing Consolidated Net Income/Loss decreased by -10.19% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$6.6 Billion $5.09 Billion $4.57 Billion $7.35 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Consolidated Net Income/Loss of AbbVie Inc.

Most recent Consolidated Net Income/Lossof ABBV including historical data for past 10 years.

Interactive Chart of Consolidated Net Income/Loss of AbbVie Inc.

AbbVie Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $752.0 $3,531.0
2020 $22.0 $2,296.0 $-757.0 $3,010.0 $4,562.0
2019 $2,801.0 $1,884.0 $741.0 $2,456.0 $7,842.0
2018 $-1,826.0 $2,747.0 $1,983.0 $2,783.0 $5,657.0
2017 $52.0 $1,631.0 $1,915.0 $1,711.0 $5,283.0
2016 $1,391.0 $1,598.0 $1,610.0 $1,354.0 $5,923.0
2015 $1,517.0 $1,239.0 $1,366.0 $1,022.0 $5,144.0
2014 $-810.0 $506.0 $1,098.0 $980.0 $1,774.0
2013 $1,128.0 $964.0 $1,068.0 $968.0 $4,128.0
2012 $1,540.0 $1,585.0 $1,267.0 $883.0 $5,275.0
2011 $1,157.0 $13.0 $1,540.0 $723.2 $3,433.0
2010 $4,178.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.